Vascular Endothelial Growth Factor Receptor

From Proteopedia

Jump to: navigation, search
Human VEGFR kinase domain complex with anti tumor inhibitor and sulfate (PDB code [[3c7q]])

Contents

3D Structures of VEGFR

Updated on 21-August-2014

VEGFR-1

1rv6 - hVEGFR-1 domain 2 + PlGF - human
1qsv - hVEGFR-1 VEGF-binding domain – NMR
2xac – hVEGFR-1D2 + hVEGF-B
3hng - hVEGFR-1 kinase domain + N-(4-Chlorophenyl)-2-((pyridin-4-ylmethyl)amino)benzamid

VEGFR-2

3kvq - hVEGFR-2 extracellular domain 7
1vr2 - hVEGFR-2 kinase domain (mutant)
2m59 - hVEGFR-2 membrane domain – NMR
2x1w, 2x1x – hVEGFR-2 IG-like domains 2 & 3 +hVEGF-C
3v2a - hVEGFR-2 + hVEGF-A
3v6b - hVEGFR-2 residues 132-548 + hVEGF-E
3efl – hVEGFR-2 kinase domain (mutant)+ motesanib
4ag8, 4agc, 4agd, 4asd, 4ase, 3vo3 - hVEGFR-2 kinase domain (mutant) + renal cell carcinoma drug
3ewh, 3cjf, 3cjg, 3vhe - hVEGFR-2 kinase domain + pyrimidine derivative
3c7q - hVEGFR-2 kinase domain + BIBF1120
3dtw - hVEGFR-2 kinase domain + benzisoxazole
3cp9, 3cpb, 3cpc, 3be2, 3b8q, 3b8r, 2qu5, 2qu6, 2p2h, 2p2i, 1ywn, 1y6a, 1y6b,3vid, 3vhk - hVEGFR-2 kinase domain + inhibitor
2oh4, 2rl5, 2xir, 3u6j, 3vnt - hVEGFR-2 kinase domain (mutant)+ inhibitor
3s35, 3s36, 3s37 - hVEGFR-2 extracellular domain 3 + Fab heavy+light chains

VEGFR-3

4bsj - hVEGFR-3 extracellular domain 4 & 5
4bsk - hVEGFR-3 extracellular domain 1 & 2 + VEGF-C

VEGF 165 receptor (neuropilin-1)

VEGF 165 receptor 2 (neuropilin-2)

See Neuropilin


Additional Resources

For additional information, see: Cancer

See Also

References

  1. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006 May;7(5):359-71. PMID:16633338 doi:10.1038/nrm1911
  2. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007 Oct;19(10):2003-12. Epub 2007 Jun 12. PMID:17658244 doi:10.1016/j.cellsig.2007.05.013
  3. Gallina P, Nohra G, Cioloca C, Meder JF, Roux FX. [Multiple cavernoma of delayed appearance] Neurochirurgie. 1994;40(5):322-5. PMID:7596453
  4. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem. 1998 Nov 20;273(47):31283-8. PMID:9813036
  5. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol. 2007 Mar;14(3):249-50. Epub 2007 Feb 11. PMID:17293873 doi:10.1038/nsmb1202
  6. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990 Apr;5(4):519-24. PMID:2158038
  7. Ji QS, Winnier GE, Niswender KD, Horstman D, Wisdom R, Magnuson MA, Carpenter G. Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2999-3003. PMID:9096335
  8. Welsh M, Songyang Z, Frantz JD, Trub T, Reedquist KA, Karlsson T, Miyazaki M, Cantley LC, Band H, Shoelson SE. Stimulation through the T cell receptor leads to interactions between SHB and several signaling proteins. Oncogene. 1998 Feb 19;16(7):891-901. PMID:9484780 doi:10.1038/sj.onc.1201607
  9. Zeng H, Sanyal S, Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem. 2001 Aug 31;276(35):32714-9. Epub 2001 Jul 2. PMID:11435426 doi:10.1074/jbc.M103130200
  10. Chen M, She H, Davis EM, Spicer CM, Kim L, Ren R, Le Beau MM, Li W. Identification of Nck family genes, chromosomal localization, expression, and signaling specificity. J Biol Chem. 1998 Sep 25;273(39):25171-8. PMID:9737977
  11. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002 Oct;2(10):795-803. PMID:12360282 doi:10.1038/nrc909
  12. Rosa DD, Ismael G, Lago LD, Awada A. Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat Rev. 2008 Feb;34(1):61-80. Epub 2007 Sep 10. PMID:17826917 doi:10.1016/j.ctrv.2007.07.019
  13. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001 Sep;7(9):987-9. PMID:11533692 doi:10.1038/nm0901-987
  14. Rosa DD, Ismael G, Lago LD, Awada A. Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat Rev. 2008 Feb;34(1):61-80. Epub 2007 Sep 10. PMID:17826917 doi:10.1016/j.ctrv.2007.07.019

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Michal Harel, Jaime Prilusky, Wayne Decatur, Alexander Berchansky

Personal tools